PARK7 and cancer: Thus, specific inhibitors targeting DJ-1 and PAD4 have been developed for cancer therapies [168, 169] Similarly, inhibitors against FN3K have also been screened based on its enzymatic activity, which have great potentials to become drug leads in the future [170–172].